SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AEROB) today announce a negative decision by the Federal Patent Court in Munich regarding the validity of one of Aerocrine’s German patents. This first instance decision is subject to appeal and does not change Medisoft’s obligation to respect the existing three infringement decisions in Germany. The Belgian counterpart of that same patent was recently declared valid and infringed by a Court in Belgium and Medisoft, which is seated in Belgium, is prohibited to manufacture and sell any of its HyPair FeNO and FeNO + machines. Aerocrine has a strong intention to appeal the German decision.
